Intermagnetics’ subsidiary wins coil contract
MRI developer Intermagnetics General’s subsidiary, IGC-Medical Advances (IGC-MAI), has won an exclusive worldwide contract from coil developer UltraImage to distribute a new line of radio-frequency MRI coils. IGC-MAI and UltraImage will also
MRI developer Intermagnetics Generals subsidiary, IGC-Medical Advances (IGC-MAI), has won an exclusive worldwide contract from coil developer UltraImage to distribute a new line of radio-frequency MRI coils. IGC-MAI and UltraImage will also collaborate on clinical applications packages for existing and future MRI applications.
IGC-MAI will market three UltraImage RF coils, all of which are compatible with existing MRI systems: a device for imaging the temporal lobe of the brain, a device for the bilateral brachial plexus, and a device for the carotid arteries. IGC-MAI expects to begin distributing the brain imaging coil early this year, pending clearance from the Food and Drug Administration. The two other coils should receive FDA clearance by the end of the year, according to Milwaukee, WI-based IGC-MAI. All three coils were introduced at Novembers RSNA conference.
UltraImage, based in Redmond, WA, was established in 1997 to develop and market RF coils designed by researchers at the University of Washingtons department of radiology. The company is a subsidiary of Pathway Medical Technologies, a technology research and development company with a focus on medical devices.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
